Article

Sponsored Content

Is Your In-House Strategy Ready For The Uncertainties Of Biologic Drug Development?

Author(s):

John Ward

The pharmaceutical industry’s past reliance on blockbuster drugs has evolved to include developing drugs that treat the needs of smaller patient populations. These drugs most often come in the form of biologics, which are an increasingly larger share of new drug approvals in the past decade, from 10 percent to 27 percent.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Content
Site Logo
August 2nd 2025

The Roadmap to Asset Performance Management in Life Science

BlueMountain
Site Logo
August 2nd 2025

Unlock the Future of Enterprise Asset Management with Agentic AI

BlueMountain
Site Logo
August 2nd 2025

From Maintenance to Compliance: A Guide to CMMS/EAM Readiness

BlueMountain
Site Logo
August 2nd 2025

Executive Summary: End-To-End Regulatory CDMO Solutions: Development, Manufacturing, and Approval

Lonza
The road to market access is long and complex. Choosing a CDMO with experienced staff can prove vital to success. In this executive summary, Praveenkumar Devakadaksham and Dr. Roché Marcel Walliser explain all the ways they help make the journey from pharmaceutical development to commercial distribution as smooth as possible. Learn more about:
Site Logo
August 2nd 2025

Executive Summary: Keys to Supplying Decentralized Trials: The Value of Direct-to-Patient Solutions and the Pharmacy-Led Model

Catalent
Site Logo
August 2nd 2025

Innovations in Pregastric Absorption Drug Delivery & Orally Disintegrating Tablets

Catalent